Management tracks: Rubius, Abingworth, Arcus

Rubius hired Greg Whitehead as SVP and chief quality officer, a newly created position. He was VP, quality at bluebird bio Inc. (NASDAQ:BLUE). Whitehead will be responsible for defining the company's quality strategy to meet global regulatory standards as Rubius Therapeutics Inc. (NASDAQ:RUBY) gets ready to bring its first engineered red blood cell therapy into the clinic via its Red Cell Therapeutics. Rubius will test its first therapy in a Phase Ib trial of RTX-134 for phenylketonuria in 2Q19 (see “Rubius Turns Immunotherapy Red”).

Abingworth hired Bali Muralidhar as partner. He was a senior partner at MVM Life Science Partners...